【导读】晚期胰腺导管腺癌（PDAC）预后不佳。单用免疫疗法的疗效有限，但尚不清楚其与化疗联合是否能产生协同抗肿瘤作用。11月25日，四川大学研究团队在期刊《Signal Transduction and Targeted Therapy》上发表了题为 ...

Leads Biolabs receives US FDA orphan drug designation for anti-PD-L1/4-1BB bispecific antibody, LBL-024 for treatment of neuroendocrine cancer: Nanjing, China Saturday, November 2 ...

According to Alnylam’s Tim Mooney, mivelsiran’s endurance is due to stabilizing tweaks the scientists made to the siRNA ...

New research shows white blood cells activated by COVID-19 may have cancer-fighting abilities, offering hope for future ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

For those looking for great candidates, here are two in the healthcare sector: Merck (NYSE: MRK) and Pfizer (NYSE: PFE). Is ...

The new drug, Jazz Pharmaceuticals’ zanidatamab, has won an FDA accelerated approval for adults with previously treated ...

上海2024年11月17日 /美通社/ -- 君实生 物（1877.HK，688180.SH）宣布，由公司自主研发的抗PD-1单抗药物特瑞普利单抗（英国商品名：LOQTORZI? ）于近日获得英国药品... 上海2024年11月17日 /美通社/ -- 君实生物（1877.HK，688180.SH）宣布，由公司自主研发的抗PD-1单抗药物特瑞普利单抗（英国商品名：LOQTORZI ® ）于近日获得 ...

PD-L1 expression was found to predict better outcomes with Opdivo and Yervoy in patients with ccRCC, while high KIM-1 levels ...

Oncolytic viruses are a very promising class of therapeutic agents, with a broad range of types. In this exclusive interview ...

We recently compiled a list of the 10 Best German Stocks To Buy Now. In this article, we are going to take a look at where ...

The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.